Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents

This study has been completed.
Information provided by (Responsible Party):
Seema Kumar, Mayo Clinic
ClinicalTrials.gov Identifier:
First received: November 16, 2012
Last updated: May 31, 2014
Last verified: May 2014
Vitamin D deficiency has been linked to endothelial dysfunction in adults. Obese adolescents have a high prevalence of Vitamin D deficiency as well as evidence of endothelial dysfunction. Our hypothesis is that supplementation of Vitamin D deficient adolescents with Vitamin D would lead to improvement in endothelial dysfunction.

Condition Intervention Phase
Endothelial Dysfunction
Vitamin D Deficiency
Dietary Supplement: Vitamin D3
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Change in flow mediated dilatation (FMD) [ Time Frame: baseline to 3 months ] [ Designated as safety issue: No ]
    Endothelial function will be assessed by FMD. Flow mediated dilatation (FMD) will be calculated as the maximal percentage increase in Brachial artery diameter (BAD) from baseline after the release of cuff occlusion.

Enrollment: 19
Study Start Date: November 2012
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vitamin D
Vitamin D supplementation at 100,000 IU once a month for 3 months
Dietary Supplement: Vitamin D3
Vitamin D 3 at 100,000 IU once a month for 3 months


Ages Eligible for Study:   12 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age 12-18 years
  2. BMI >95% for age and gender
  3. 25 (OH) D levels less than 30 ng/ml

Exclusion Criteria:

  1. 25 (OH) D levels >30 ng/mL
  2. Serum calcium >10.4 mg/dL
  3. Serum phosphorus > 4.7 mg/dl
  4. Pregnancy or nursing
  5. Current cancer
  6. Patients on vitamin D3 supplementation exceeding 400 IU/day
  7. Hypertension defined as Blood Pressure over the 95th percentile for age, gender and height
  8. Dietary calcium intake exceeding 1500 mg/day,
  9. Hepatic or renal disorders
  10. Type 1 or type 2 diabetes mellitus
  11. Subjects receiving insulin, metformin, or oral hypoglycemic medications
  12. Subjects with malabsorption disorders (celiac disease, cystic fibrosis,inflammatory bowel disease)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01746264

United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Principal Investigator: Seema Kumar, MD Mayo Clinic
  More Information

No publications provided

Responsible Party: Seema Kumar, PI, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01746264     History of Changes
Other Study ID Numbers: 12-006349 
Study First Received: November 16, 2012
Last Updated: May 31, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
Endothelial dysfunction
Vitamin D deficiency

Additional relevant MeSH terms:
Vitamin D Deficiency
Deficiency Diseases
Nutrition Disorders
Vitamin D
Bone Density Conservation Agents
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on February 04, 2016